[{"orgOrder":0,"company":"Champions Oncology","sponsor":"GigaMune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Champions Oncology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Champions Oncology \/ Champions Oncology","highestDevelopmentStatusID":"3","companyTruncated":"Champions Oncology \/ Champions Oncology"}]

Find Clinical Drug Pipeline Developments & Deals by Champions Oncology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the terms of the agreement, Champions will have the right to select a specified number of TCRs from the library for further, wholly owned, development. The remaining libraries will be jointly owned by Champions and GigaMune for commercialization, w...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 15, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : GigaMune

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank